A comparative study of efficacy and safety of oral griseofulvin versus oral terbinafine in patients with tinea capitis at a tertiary care hospital

Geetha A; Ramya Y S; Divakar; Raghav M V

doi:10.5455/njppp.2023.13.03159202325042023

2024, Vol: 14, Issue: 10

14 / 10Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Original Research
Online Published: 09 May 2023

Natl J Physiol Pharm Pharmacol. 2023; 13(11): 2353-2357

doi: 10.5455/njppp.2023.13.03159202325042023

A comparative study of efficacy and safety of oral griseofulvin versus oral terbinafine in patients with tinea capitis at a tertiary care hospital

Geetha A, Ramya Y S, Divakar, Raghav M V.

Abstract
Background: Tinea capitis is a common dermatophytic infection of the scalp hair follicle and the intervening skin with an incidence in rural India of about 28.5%. Antifungal agent terbinafine which requires a shorter course of treatment than conventional griseofulvin is being compared.

Aims and Objectives: The objective of the current study was to compare the efficacy and safety of oral griseofulvin and oral terbinafine in tinea capitis among children aged 3–14 years.

Materials and Methods: An open-label, prospective, comparative study was conducted with clearance and approval from the Institutional Ethics Committee, and assent was taken from all participants. Children between the ages of 3 and 14 years were enrolled for over 24 months. Patients with clinically diagnosed and laboratory-confirmed tinea capitis were randomized into two groups of 50 each. Group A was given oral griseofulvin for 8 weeks and Group B was given oral terbinafine for 4 weeks.

Results: Early response was obtained in Group B treated with terbinafine, and a statistically significant reduction in clinical symptoms was obtained at 4 weeks compared to griseofulvin with P = 0.044. Mycological cure was achieved at the end of 6 weeks in the terbinafine group, with P = 0.034 compared to the griseofulvin group in which 3 patients remained KOH positive at 8 weeks.

Conclusion: Both drugs were well tolerated with no serious adverse effects. Terbinafine is an effective alternative to griseofulvin in pediatric patients with tinea capitis with a shorter duration of treatment and fewer adverse effects.

Key words: Griseofulvin; Terbinafine; Tinea Capitis; Pediatric Fungal Infection

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Geetha A Articles by Ramya Y S Articles by Divakar Articles by Raghav M V
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

A G, S RY, Divakar , V RM. A comparative study of efficacy and safety of oral griseofulvin versus oral terbinafine in patients with tinea capitis at a tertiary care hospital. Natl J Physiol Pharm Pharmacol. 2023; 13(11): 2353-2357. doi:10.5455/njppp.2023.13.03159202325042023

Web Style

A G, S RY, Divakar , V RM. A comparative study of efficacy and safety of oral griseofulvin versus oral terbinafine in patients with tinea capitis at a tertiary care hospital. https://www.njppp.com/?mno=147742 [Access: October 03, 2024]. doi:10.5455/njppp.2023.13.03159202325042023

AMA (American Medical Association) Style

A G, S RY, Divakar , V RM. A comparative study of efficacy and safety of oral griseofulvin versus oral terbinafine in patients with tinea capitis at a tertiary care hospital. Natl J Physiol Pharm Pharmacol. 2023; 13(11): 2353-2357. doi:10.5455/njppp.2023.13.03159202325042023

Vancouver/ICMJE Style

A G, S RY, Divakar , V RM. A comparative study of efficacy and safety of oral griseofulvin versus oral terbinafine in patients with tinea capitis at a tertiary care hospital. Natl J Physiol Pharm Pharmacol. (2023), [cited October 03, 2024]; 13(11): 2353-2357. doi:10.5455/njppp.2023.13.03159202325042023

Harvard Style

A, G., S, . R. Y., Divakar, . & V, . R. M. (2023) A comparative study of efficacy and safety of oral griseofulvin versus oral terbinafine in patients with tinea capitis at a tertiary care hospital. Natl J Physiol Pharm Pharmacol, 13 (11), 2353-2357. doi:10.5455/njppp.2023.13.03159202325042023

Turabian Style

A, Geetha, Ramya Y S, Divakar, and Raghav M V. 2023. A comparative study of efficacy and safety of oral griseofulvin versus oral terbinafine in patients with tinea capitis at a tertiary care hospital. National Journal of Physiology, Pharmacy and Pharmacology, 13 (11), 2353-2357. doi:10.5455/njppp.2023.13.03159202325042023

Chicago Style

A, Geetha, Ramya Y S, Divakar, and Raghav M V. "A comparative study of efficacy and safety of oral griseofulvin versus oral terbinafine in patients with tinea capitis at a tertiary care hospital." National Journal of Physiology, Pharmacy and Pharmacology 13 (2023), 2353-2357. doi:10.5455/njppp.2023.13.03159202325042023

MLA (The Modern Language Association) Style

A, Geetha, Ramya Y S, Divakar, and Raghav M V. "A comparative study of efficacy and safety of oral griseofulvin versus oral terbinafine in patients with tinea capitis at a tertiary care hospital." National Journal of Physiology, Pharmacy and Pharmacology 13.11 (2023), 2353-2357. Print. doi:10.5455/njppp.2023.13.03159202325042023

APA (American Psychological Association) Style

A, G., S, . R. Y., Divakar, . & V, . R. M. (2023) A comparative study of efficacy and safety of oral griseofulvin versus oral terbinafine in patients with tinea capitis at a tertiary care hospital. National Journal of Physiology, Pharmacy and Pharmacology, 13 (11), 2353-2357. doi:10.5455/njppp.2023.13.03159202325042023

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article